Venous thromboembolism prophylaxis in medical patients: Future perspectives

Thrombosis Research

Volumn 116, Issue 5, 2005, Pages 365-375

  Imberti, Davide ^a,c   Prisco, Domenico ^b  

^a Hospital of Piacenza   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c GUGLIELMO DA SALICETO HOSPITAL   (Italy)

Author keywords

Medical patients; Prophylaxis; Risk factors; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; ENOXAPARIN; NADROPARIN;

BLEEDING; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; DEEP VEIN THROMBOSIS; DRUG SAFETY; EPIDEMIOLOGICAL DATA; EVALUATION; HOSPITALIZATION; HUMAN; INCIDENCE; LUNG EMBOLISM; MEDICAL INFORMATION; META ANALYSIS; MORTALITY; PHLEBOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; VALIDATION PROCESS; VENOUS THROMBOEMBOLISM;

BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 23944468072     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.01.001     Document Type: Review

References (45)

1. W.H. Geerts, G.F. Pineo, J.A. Heit, D. Berqvist, M.R. Lassen, and C.W. Colwell Prevention of venous thromboembolism Chest 126 2004 338S 400S
2. A.N. Nicolaides Prevention of venous thromboembolism. International consensus statement. Guidelines compiled in accordance with the scientific evidence Int. Angiol. 20 2001 1 37
3. J.A. Caprini, J.I. Arcelus, and J.J. Reyna Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease Semin. Haematol. 38 Suppl. 5 2001 12 19
4. M. Samama, A. Cohen, M. Darmon, L. Desjardins, A. Eldor, and C. Janbon A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients N. Engl. J. Med. 341 1999 793 800
5. B. Lindblad, N. Sternby, and D. Berqvist Incidence of venous thromboembolism verified by necroscopy over 30 years BMJ 302 1991 709 711
6. P. Mismetti, S. Laporte-Simitsidis, B. Tardy, M. Cucherat, A. Buchmuller, and D. Juillard-Delsart Prevention of venous thromboembolism in internal medicine with unfractioned or low-molecular-weight heparins: a meta-analysis of randomised clinical trials Thromb. Haemost. 83 2000 14 19
7. A. Leizorovicz, A.T. Cohen, G. Turpie, C.G. Olsson, P.T. Vaitkus, and S.Z. Goldhaber Randomized, placebo controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients Circulation 110 2004 874 879
8. Gruppo di lavoro per le linee guida sul tromboembolismo venoso della Società Italiana per lo Studio dell'Emostasi e della Trombosi. Profilassi del tromboembolismo venoso in medicina Haematologica 88 Suppl. 18 2003 50 53
9. Gruppo di lavoro per le linee guida sulla profilassi del tromboembolismo venoso in medicina e sulla profilassi e la terapia del tromboembolismo venoso in oncologia medica della Società Italiana per lo Studio del'Emostasi e della Trombosi, Linee guida della Società Italiana per lo Studio dell'Emostasi e della Trombosi 2004 Haematologica 89 Suppl. 2 2004 27 29
10. Thromboembolic Risk Factors Consensus Group Risk of and prophylaxis for venous thromboembolism in hospital patients Br. Med. J. 79 1992 1 17
11. M.M. Samama, O.E. Dahl, P. Mismetti, D.J. Quinlan, N. Rosencher, and M. Cornelis Individualizing the risk of venous thromboembolism in medical and surgical patients: development of the decision matrix for VTE prophylaxis J. Thromb. Haemost. 1 Suppl. 1 2003 OC436
12. M.M. Samama, O.E. Dahl, D.J. Quinlan, P. Mismetti, and N. Rosencher Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool Haematologica 88 2003 1410 1421
13. A.T. Cohen, R. Alikhan, J. Arcelus, J.-F. Bergmann, S. Hass, and G. Merli A risk assessment model for identifying medical patients who should receive thombopropylaxis J. Thromb. Haemost. 1 Suppl. 1 2003 OC437
14. S.Z. Goldhaber, K. Dunn, and R.C. MacDougall New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment Chest 118 2000 1680 1684
15. W. Ageno, A. Squizzato, F. Ambrosini, F. Dentali, C. Marchesi, and V. Mera Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns Haematologica 87 2002 746 750
16. S.Z. Goldhaber, V.F. Tapson the DVT FREE Steering Committee A prospective registry of 5451 patients with ultrasound-confirmed deep vein thrombosis Am. J. Cardiol. 93 2004 259 262
17. F.A. Anderson Jr., H. Decousus, J.F. Bergmann, S. Chong, J. Froelich, and J. Johnson A multinational observational cohort study in hospitalized medical patients of practices in prevention of venous thromboembolism and clinical outcomes: findings of the International Medical Prevention Registry of Venous Thromboembolism (IMPROVE) J. Thromb. Haemost. 1 Suppl. 1 2003 P1438
18. M. Monreal, A.K. Kakkar, J.A. Caprini, R. Barba, F. Uresandi, and R. Valle The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Finding from the RIETE registry J. Thromb. Haemost. 2 2004 1892 1898
19. J. Lacherade, D. Cook, D. Heyland, C. Chrusch, L. Brochard, and C. Brun-Buisson Prevention of venous thromboembolism in critically ill medical patients: a Franco-Canadian cross-sectional study J. Crit. Care 18 2003 228 237
20. J. Labarere, J.-L. Bosson, J.-P. Brion, M. Fabre, B. Imbert, and P. Carpentier Validation of a clinical guideline on prevention of venous thromboembolism in medical inpatients: a before-and-after study with systematic ultrasound examination J. Intern. Med. 256 2004 338 348
21. J.W. Eikelboom, D.J. Quinlan, and J.D. Douketis Extended duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials Lancet 358 2001 9 15
22. R.D. Hull, G.F. Pineo, P.D. Stein, A.F. Mah, S.M. MacIsaac, and O.E. Dahl Extended out of hospital low-molecular-weight heparin prophylaxis against venous thromboembolism in patients after elective hip arthroplasty: a systematic review Ann. Intern. Med. 135 2001 858 869
23. D. Berqvist, G. Agnelli, A.T. Cohen, A. Eldor, P.E. Nilsson, and A. Le-Moigne-Amrani Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer N. Engl. J. Med. 346 2002 975 980
24. B. Gardlund Randomised, controlled trial of low-dose heparin for prevention of fatal PE in patients with infectious diseases. The heparin prophylaxis study group Lancet 347 1996 1357 1361
25. J.L. Bosson, J. Labarere, M.A. Sevestre, J. Belmin, L. Beyssier, and A. Elias Deep vein thrombosis in elderly patients hospitalized in subacute care facilities Arch. Intern. Med. 163 2003 2613 2618
26. R. Hull, S. Schellong, V. Tapson, R. Yusen, M. Monreal, and M. Samama Extended thromboprophylaxis with enoxaparin in acutely ill patients with prolonged periods of immobilisation: the EXCLAIM study J. Thromb. Haemost. 1 Supp. 1 2003 OC397
27. E. Oger, L. Bressolette, M. Nonent, K. Lacut, B. Guias, and F. Couturaud High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. The TADEUS project Thromb. Haemost. 88 2002 592 597
28. E.J. Roth, L. Lovell, R.L. Harvey, A.W. Heinemann, P. Semick, and S. Diaz Incidence and risk factors for medical complications during stroke rehabilitation Stroke 32 2001 523 529
29. G. Scannapieco, M. Rossi, F. Baldessin, M. Rattazzi, P. Pavan, and P. Pauletto Incidenza e fattori di rischio per tromboembolia venosa nei pazienti ricoverati in lungodegenza Giorn. Ital. Med. Int. 2 Suppl. 2 2002 101a
30. M.E. Gatt, O. Paltiel, and M. Bursztyn Is prolonged immobilization a risk factor for symptomatic venous thromboembolism in elderly bedridden patients? Thromb. Haemost. 91 2004 538 543
31. A. Koch, S. Bouges, S. Ziegler, H. Dinkel, J.P. Daures, and N. Victor Low molecular weight heparin and unfractioned heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses Br. J. Surg. 84 1997 750 759
32. A. Lamy, X. Wang, R. Kent, K.M. Smith, and A. Gafni Economic evaluation of the MEDENOX trial: a Canadian prospective Can. Respir. J. 9 2002 169 177
33. M. Pechevis, B. Detournay, C. Pribil, F. Fagnani, and E. Eschwege Economic evaluation of enoxaparin vs placebo for the prevention of venous thromboembolism in acutely ill medical patients Value Health 3 2000 389 396
34. Ac Lloyd, P.M. Anderson, and D.J. Quinlan Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients J. Med. Econ. 4 2001 99 113
35. R. Dahan, D. Houlbert, C. Caulin, E. Cuzin, C. Viltart, and M. Woler Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial Haemostasis 16 1986 159 164
36. F. Fraisse, L. Holzapfel, J.M. Couland, G. Simonneau, B. Bedock, and M. Feissel Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD Am. J. Respir. Crit. Care Med. 161 2000 1109 1114
37. J.F. Bergmann, and C. Caulin Heparin prophylaxis in bedridden patients Lancet 348 1996 205 206
38. J.F. Bergmann, and E. Neuhart A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The enoxaparin in medicine study group Thromb. Haemost. 7 1996 529 534
39. E. Lechler, W. Schramm, and C.W. Flosbach The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group Haemostasis 26 Suppl. 2 1996 49 56
40. F.X. Kleber, C. Witt, G. Vogel, K. Koppenhagen, U. Schomaker, C.W. Flosbach for The PRINCE Study Group Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease Am. Heart J. 14 2003 614 621
41. J. Harenberg, P. Roebruck, and D.L. Heene Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group Haemostasis 26 1996 127 139
42. A. Kierkegaard, and L. Norgren Graduated compression stockings in the prevention of deep vein thrombosis in patients with acute myocardial infarction Eur. Heart J. 14 1993 1365 1368
43. K.W. Muir, A. Watt, C. Baxter, D.G. Grosset, and K.R. Lees Randomized trial of graded compression stockings for prevention of deep vein thrombosis after acute stroke Q. J. Med. 93 2000 359 364
44. A.T. Cohen, B.L. Davidson, A.S. Gallus, M.R. Lassen, W. Tomkowski, and A.G.G. Turpie Fondaparinux for the prevention of VTE in acutely ill medical patients Blood 102 11 2003 15a
45. M. Hillbom, T. Erila, J. Sotaniemi, T. Tatlisumak, S. Sarna, and M. Kaste Enoxaparin vs heparin for prevention of deep vein thrombosis in acute ischaemic stroke: a randomized, double blind study Acta. Neurol. Scand. 106 2002 84 92